Drug intelligence / Profile preview

LSHP001

Development stage: Preclinical
Lead developer: Monyan Pharmaceutical
Administration: Oral

Overview

LSHP001 is a Traditional Chinese Medicine (TCM) candidate classified as TCM Class 2, currently under development by Monyan Pharmaceutical. It is being investigated for the treatment of burning mouth syndrome (BMS), a chronic condition characterized by a burning sensation in the mouth without an obvious underlying medical or dental cause. The drug is currently in the IND-enabling phase, with an Investigational New Drug (IND) application planned for 2027.

Beyond the preview

Go deeper on LSHP001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LSHP001.

Explore the full profile